Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
A Post-marketing Clinical Study of a Third Dose of the Inactivated SARS-CoV-2 Vaccine (Vero Cells) (Produced in Beijing): Immunogenicity, Safety and Antibody Persistence Assessments in Patients With Hypertension and/or Diabetes
Sponsor: Beijing Institute of Biological Products Co Ltd.
A PHASE4 clinical study on COVID-19 Pneumonia, this trial is ongoing. The trial is conducted by Beijing Institute of Biological Products Co Ltd. and has accumulated 6 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Nov 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Not Yet Recruiting → Unknown Status
-
Feb 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE4
-
Nov 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE4
▶ Show 1 earlier version
-
Dec 2021 — Nov 2022 [monthly]
Not Yet Recruiting PHASE4
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Institute of Biological Products Co Ltd.
- Center for Disease Control and Prevention, Fujian
- China National Biotec Group Company Limited
- Guizhou Center for Disease Control and Prevention
- Hunan Provincial Center for Disease Control and Prevention
For direct contact, visit the study record on ClinicalTrials.gov .